Hong Kong’s Global Health Playbook: Patrick Lau on Biotech, Medtech, and Collaborative Innovation

From aging populations and skyrocketing healthcare costs to unequal access and fragile supply chains, the global health landscape is under pressure. Biotech and medtech innovations often stay out of reach for emerging markets, while the world desperately needs scalable, affordable fixes. So, how can the international community spark innovation, boost access, and drive real change? Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council (HKTDC), brings a fresh take. In his 2025 ASGH interview, he showcased how Hong Kong is stepping up to tackle these issues. With his hands-on role overseeing service promotion, merchandise trade, innovation, and international partnerships, Lau’s insights highlight Hong Kong’s strengths in biotech, medtech, silver health, startups, and collaboration. 

Hong Kong’s Competitive Edge in Biotech

Building on Hong Kong’s potential to lead, Lau kicked off with a strong point about its biotech sector. He expressed confidence in its rapid growth. “We have two of the best medical schools,” he said, pointing to the University of Hong Kong and the Chinese University of Hong Kong. Renowned professors like Nancy Ip, a pioneer in Alzheimer’s research, spearhead efforts here. Lau noted growing government backing. The Health Bureau is crafting an FDA-like registration system. “Hong Kong will pay more attention to this,” he added. The Greater Bay Area adds a policy boost, with over 100 products already entering mainland China via the medical device connect program.

This strength carries global weight. Biotech breakthroughs in Hong Kong can tackle universal issues like Alzheimer’s, benefiting aging populations in Europe and North America. Government support echoes trends in the U.S. and Germany, where biotech investment is rising. With 86 million people, the Greater Bay Area serves as a testing ground for solutions scalable to India or Brazil. Plus, Hong Kong’s link to China’s global push connects it to emerging markets hungry for affordable health options. Moving forward, this foundation sets the stage for tackling medtech challenges next.

Hong Kong’s Role in the Global Medtech Market

Shifting from biotech to medtech, Lau’s insights reveal another layer of Hong Kong’s health prowess. He outlined the city’s robust ecosystem. “We have wonderful doctors, medical schools, and professors,” he noted. Hong Kong taps into the Greater Bay Area’s $2 trillion GDP and 86 million population, creating a massive market for testing and manufacturing. Lau highlighted financial perks. Companies can list pre-revenue under Chapter 18A and 18C rules. A new FDA-like approval system is on the horizon. “We have a strong intellectual property system and common law,” he said. Hong Kong also acts as a gateway to mainland China.

On the global stage, this makes Hong Kong a medtech hotspot. Its financial setup draws startups from the U.S. or Singapore. The Greater Bay Area’s market rivals South Korea’s, ideal for Asia-Pacific innovations. The approval system could mirror Singapore’s Health Sciences Authority, easing the path for international firms. For example, a German medtech company could test devices here before hitting China’s market. This gateway role addresses access issues, smoothly leading us to the power of collaboration.

Addressing Global Health Challenges Through Collaboration

With medtech laying the groundwork, Lau turned to a critical solution: collaboration. He stressed the need for global unity. “Geopolitical issues should be set aside,” he urged. Emerging markets crave affordable healthcare, and Lau flagged supply chain disruptions as a hurdle. “Some emerging countries need low-cost alternatives,” he said. He pointed to exhibitors offering budget-friendly solutions. “If medicine is too expensive, it equals no medicine,” he stated. Collaboration can bridge this gap and deliver help where it’s needed.

This approach hits home worldwide. Supply chain woes, lingering from the 2020-2021 pandemic, still plague Africa and Southeast Asia. Affordable care is a lifeline in places like Nigeria, where costs block access. Lau’s call aligns with WHO efforts for equitable health, like low-cost diagnostics reaching rural Indonesia. Partnerships, such as the UCL-HKUST Alzheimer’s team, could speed up solutions for millions across Japan and the U.S. This collaborative spirit naturally flows into supporting startups.

Showcasing Global Startups and Deal-Making

Building on collaboration, Lau highlighted startups as key players. Over 100 exhibitors, mostly startups, showcased new tech. They hailed from Hong Kong, mainland China, and overseas, including Finland. Lau met a Finnish exhibitor with a mood-detecting device. “We connect them with partners to commercialize,” he said. The HKTDC arranged 300 deal-making meetings. Past wins included AI tie-ups with hospitals like IHH and Glen Eagle. One AI tool screens patients for breathing rate and blood pressure, freeing nurses for critical tasks.

This has worldwide ripple effects. Diverse startups, like the Finnish one, show Hong Kong’s global pull. AI tools could revolutionize understaffed hospitals in India or South Africa. Deal-making scales innovations, such as a Hong Kong diagnostic detecting 50 pathogens, aiding Brazil’s infectious disease fight. The Greater Bay Area’s manufacturing keeps costs down, reaching low-income areas like sub-Saharan Africa. This startup momentum segues into tackling silver health.

Focus on Silver Health and Alzheimer’s Research

Transitioning to aging populations, Lau zeroed in on silver health. “Silver health matters because of Asia’s aging population,” he said. He expanded on Alzheimer’s research, noting a partnership between Sir John Hardy from UCL and Nancy Ip from HKUST. They’re working on early diagnosis and treatment. “It’s exciting to tackle this terrible disease,” Lau added. This focus addresses a pressing challenge across regions.

Aging is a global concern. Japan, with 28% of its population over 65, and Europe, especially Italy, face similar issues. Alzheimer’s impacts over 55 million people worldwide, per WHO stats. Hong Kong’s research could yield breakthroughs for U.S. or German patients. Affordable solutions from the Greater Bay Area could help aging communities in Thailand. This effort underscores Hong Kong’s role in a universal health crisis, wrapping up with its broader impact.

Why This Matters to the International Community

Pulling it all together, Lau’s insights position Hong Kong as a health innovation leader. Its biotech and medtech ecosystems are churning out solutions for tough challenges like Alzheimer’s, which hits over 55 million people worldwide per WHO stats. The Greater Bay Area’s $2 trillion GDP and 86 million people amplify this, scaling ideas for diverse markets. Startups are thriving too, thanks to 300 deal-making sessions that link them globally—think AI tools for understaffed African clinics. The focus on silver health and Alzheimer’s tackles aging populations, while affordable care bridges gaps in places like Nigeria. Whether you’re in North America, Europe, or Asia, Hong Kong shines as a dynamic hub, delivering practical fixes for aging, disease, and access issues as of May 27, 2025.

Digging deeper, Hong Kong’s biotech scene, boosted by top schools and stars like Nancy Ip, could lead Alzheimer’s breakthroughs. With Japan at 28% over 65 and Italy facing similar trends, early diagnosis here could help the U.S. and Europe. The Greater Bay Area’s scale rivals South Korea’s, offering a testing ground for India or Brazil’s healthcare gaps. Medtech gets a lift from pre-revenue listings under Chapter 18A and 18C, drawing startups from Singapore or London. An upcoming FDA-like system might streamline regs, much like the EU’s approach, letting a German firm test devices for China’s market—key after 2020-2021 supply chain hiccups.

Collaboration’s the heart of it. Lau pushes past geopolitics, with partnerships like UCL-HKUST speeding low-cost diagnostics to rural Indonesia or Nigeria, aligning with WHO’s equity push. Those 300 deals bring innovations like pathogen tests to India or Africa, with the Bay Area’s manufacturing keeping costs down—maybe even inspiring Silicon Valley to scale for emerging markets. Silver health research could ease strains in Thailand or Germany, offering a roadmap. Hong Kong’s not just innovating—it’s ensuring those wins reach where they’re needed most, tackling global health head-on.

Related posts:

Climbing the MedTech Mountain: How Startups can Tackle Clinical, Payer, and Exit Peaks Genespire Presents Promising Preclinical Data on Liver-Directed Gene Therapy for MMA at ASGCT 2025 ASGH 2025 Tackles Global Healthcare’s Core Challenges: Equity and Sustainability How Anxiety and Depression Weigh Us Down—From Teen Years to Adulthood

Author

Bernice Lottering